Skip to content

US · GDTC · BIOTECHNOLOGY

CytoMed Therapeutics Limited (GDTC) intrinsic value and stock valuation

$0.76as of 2026-11-21 · Mkt cap 9.72M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

CytoMed Therapeutics Limited DCF and intrinsic value

InvestorsCraft values GDTC with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from GDTC’s statements →

CytoMed Therapeutics Limited Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Singapore, CE 149544 w2.cytomed.sg

How the business is doing

Fiscal 2019–2025, USD

Revenue
$320K
20192025
Net income
-$-3.92M
20192025
Free cash flow
-$-4.4M
20192025
Total equity
$6.85M+70.2% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$320K$70K$510K$370K$0.00
Operating income-$-4.52M-$-3.13M-$-1.58M-$-2.28M-$-1.16M
Net income-$-3.92M-$-2.52M-$-4.14M-$-3.06M-$-2.07M
EPSd-$-336.48K-$-218.37K-$-389.46K-$-386.36K-$-298.7K
Operating cash flow-$-3.7M-$-2.71M-$-3.54M-$-1.4M-$-1.72M
Capital expenditure-$-700K-$-1.4M-$-60K-$-480K-$-580K
Free cash flow-$-4.4M-$-4.11M-$-3.6M-$-1.88M-$-2.3M
Total assets$7.98M$10.1M$12.4M$5.25M$6.1M
Total debt$480K$460K$450K$4.24M$3.27M
Net debt-$-1.61M-$-4.51M-$-8.57M$2.65M$750K
Total equity$6.85M$9.04M$11.3M$590K$2.6M
Cash and short-term investments$2.1M$4.97M$9.02M$1.59M$2.53M
Income statement
20252024202320222021
Revenue$320K$70K$510K$370K$0.00
Cost of revenue$1.21M$20K$0.00$110K$0.00
Gross profit-$-890K$50K$510K-$-110K$110K
Research and development expenses$2.18M$1.91M$1.59M$1.52M$1.09M
Selling, general and administrative expenses$1.44M$1.27M$490K$600K$590K
Other expenses$10K$10K$0.00$60K-$-410K
Operating expenses$3.63M$3.18M$2.08M$2.17M$1.27M
Cost and expenses$4.84M$3.2M$2.09M$2.28M$1.89M
Interest income$120K$320K$280K$0.00$0.00
Interest expense$20K$20K$50K$120K$120K
Depreciation and amortization$220K$130K$100K$390K$330K
Ebitda-$-4.3M-$-1.99M-$-3.89M-$-1.47M-$-1.42M
Operating income-$-4.52M-$-3.13M-$-1.58M-$-2.28M-$-1.16M
Total other income/expenses, net$590K$550K-$-2.56M-$-770K-$-900K
Income before tax-$-3.93M-$-2.58M-$-4.14M-$-3.05M-$-2.06M
Income tax expense$0.00-$-50K$0.00$0.00$0.00
Net income-$-3.92M-$-2.52M-$-4.14M-$-3.06M-$-2.07M
Weighted average shares outstanding$11.7M$11.5M$10.6M$7.92M$6.93M
Weighted average diluted shares outstanding$11.7M$11.5M$10.6M$7.92M$6.93M
Balance sheet
20252024202320222021
Cash and short-term investments$2.1M$4.97M$9.02M$1.59M$2.53M
Net receivables$100K$20K$0.00$0.00$0.00
Inventory$1.07M$840K$680K$580K$430K
Total current assets$3.66M$6M$10.1M$2.51M$3.29M
Property, plant and equipment, net$3.69M$3.25M$2.07M$2.49M$2.5M
Goodwill and intangible assets$120K$90K$10K$20K$30K
Long-term investments$20K$220K$200K$240K$270K
Total non-current assets$4.32M$4.07M$2.28M$2.75M$2.81M
Total assets$7.98M$10.1M$12.4M$5.25M$6.1M
Accounts payable$120K$40K$20K$10K$50K
Short-term debt$60K$50K$40K$3.76M$2.71M
Deferred revenue$180K$0.00$0.00$0.00$0.00
Total current liabilities$710K$610K$720K$4.18M$2.94M
Long-term debt$420K$420K$410K$480K$560K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$420K$420K$410K$480K$560K
Capital lease obligations$70K$30K$10K$10K$20K
Total liabilities$1.13M$1.02M$1.13M$4.66M$3.5M
Common stock$24.7M$23.8M$23.8M$8.95M$6.56M
Retained earnings-$-18.83M-$-14.84M-$-12.37M-$-8.24M-$-5.08M
Accumulated other comprehensive income (loss)$600K$20K-$-140K-$-130K$1.11M
Total equity$6.85M$9.04M$11.3M$590K$2.6M
Total investments$20K$220K$200K$240K$290K
Total debt$480K$460K$450K$4.24M$3.27M
Net debt-$-1.61M-$-4.51M-$-8.57M$2.65M$750K
Cash flow statement
20252024202320222021
Net income-$-4M-$-2.52M-$-4.14M-$-3.15M-$-2.06M
Depreciation and amortization$400K$340K$380K$390K$330K
Stock-based compensation$690K$0.00$0.00$0.00$0.00
Change in working capital-$-490K-$-80K-$-10K-$-150K-$-430K
Accounts receivable-$-560K-$-80K-$-10K-$-150K-$-430K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-3.7M-$-2.71M-$-3.54M-$-1.4M-$-1.72M
Investments in property, plant and equipment-$-640K-$-1.4M-$-60K-$-480K-$-580K
Acquisitions, net$1.22M$0.00$0.00$0.00$0.00
Net cash used for investing activities$930K$1.13M-$-2.73M-$-480K-$-830K
Common stock issued$280K$0.00$0.00$0.00$4.02M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$210K-$-60K$10.9M$970K$4.18M
Net change in cash-$-2.6M-$-1.53M$4.63M-$-940K$1.61M
Cash at end of period$2.1M$4.7M$6.21M$1.56M$2.52M
Operating cash flow-$-3.7M-$-2.71M-$-3.54M-$-1.4M-$-1.72M
Capital expenditure-$-700K-$-1.4M-$-60K-$-480K-$-580K
Free cash flow-$-4.4M-$-4.11M-$-3.6M-$-1.88M-$-2.3M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About CytoMed Therapeutics Limited

        CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.

        CEO
        Chee Kong Choo
        Employees
        42
        Beta
        0.05

        Explore

        Frequently asked questions

        What is the intrinsic value of CytoMed Therapeutics Limited (GDTC)?

        InvestorsCraft does not currently publish an intrinsic value for GDTC. How the IC value is calculated.

        Is GDTC undervalued?

        InvestorsCraft does not publish an undervaluation signal for GDTC at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.